A Phase II Trial of Erlotinib As Front-Line Treatment in Clinically Selected Patients With Non–Small-Cell Lung Cancer
Nikolaos Vardakis
Clinical Lung Cancer, 2012
View PDFchevron_right
ErbB2 Receptor in Breast Cancer: Implications in Cancer Cell Migration, Invasion and Resistance to Targeted Therapy
Sara Cabodi
Breast Cancer - From Biology to Medicine, 2017
View PDFchevron_right
Targeting the EGFR and the PKB pathway in cancer
Shoshana Klein
Current Opinion in Cell Biology, 2009
View PDFchevron_right
What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer?
Ricardo Caponero
Annals of Oncology, 2009
View PDFchevron_right
EGFR-Ligand Signaling in Breast Cancer Metastasis: Recurring Developmental Themes
David Riese
Breast Cancer - Carcinogenesis, Cell Growth and Signalling Pathways, 2011
View PDFchevron_right
Sensitivity and resistance to EGF-R inhibitors
Thomas Valerius
mAbs, 2009
View PDFchevron_right
ErbB-Inhibitory Protein: A Modified Ectodomain of Epidermal Growth Factor Receptor Synergizes with Dasatinib to Inhibit Growth of Breast Cancer Cells
Bhaumik Patel
Molecular Cancer Therapeutics, 2010
View PDFchevron_right
Breast cancers with EGFR and HER2 co‑amplification favor distant metastasis and poor clinical outcome
Tianjie Pu
Oncology Letters
View PDFchevron_right
Clinical and molecular aspects of breast cancer: Targets and therapies
Glauber Leitao
Biomedicine & Pharmacotherapy, 2018
View PDFchevron_right
Immunobiological Aspects of erbB Receptors in Breast Cancer
Mark Greene
1999
View PDFchevron_right
ErbB receptor tyrosine kinase inhibitors as therapeutic agents
tawhid ahmad
Frontiers in Bioscience, 2002
View PDFchevron_right
Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer
Michele Tursi
Breast Cancer Research and Treatment, 2009
View PDFchevron_right
Testing for erbB-2 by Immunohistochemistry in Breast Cancer
Craig Allred
American Journal of Clinical Pathology, 2000
View PDFchevron_right
Erratum to: “A novel role for ezrin in breast cancer angio/lymphangiogenesis”
Yolanda Madarnas
Breast Cancer Research, 2015
View PDFchevron_right
IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR
Estrella Levy
Breast Cancer Research and Treatment, 2011
View PDFchevron_right
Data from ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer
Olle Stål
2023
View PDFchevron_right
Systemic treatment of early breast cancer-a biological perspective
Sally Greenberg
Journal of Surgical Oncology, 2011
View PDFchevron_right
Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor
JOSÉ JIMENEZ
Clinical Cancer Research, 2010
View PDFchevron_right
Second consensus on medical treatment of metastatic breast cancer
L. Petruzelka
Annals of Oncology, 2006
View PDFchevron_right
Systemic Therapy of Metastatic Breast Cancer
Carsten Rose
Acta Oncologica, 1990
View PDFchevron_right
Evidence for the use of chemotherapy in breast cancer
jean-marc nabholtz
International Journal of Clinical Oncology, 2002
View PDFchevron_right
Synergistic inhibition of SCR1- and ERBB2-driven brain metastatic breast cancer cells
Zain Jandial
Journal of Cancer Metastasis and Treatment, 2019
View PDFchevron_right
A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors
Paula Fracasso
Clinical Cancer Research, 2009
View PDFchevron_right
Amplified in Breast Cancer 1 in Human Epidermal Growth Factor Receptor-Positive Tumors of Tamoxifen-Treated Breast Cancer Patients
Kirsten Nielsen
Clinical Cancer Research, 2007
View PDFchevron_right
C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer
Vahur Valvere
European Journal of Cancer, 2002
View PDFchevron_right
Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer
Isabele Small
Cancer, 2014
View PDFchevron_right
Cooperative but distinct early co-signaling events originate from ERBB2 and ERBB1 receptors upon trastuzumab treatment in breast cancer cells
Katia Cortese
Oncotarget, 2017
View PDFchevron_right
Aromatase inhibitors in breast cancer
Manisha Kotadiya, jaydeep savaliya
The American Journal of Geriatric Pharmacotherapy, 2004
View PDFchevron_right
EGFR genomic alterations in cancer: prognostic and predictive values
Corrado Ficorella
Frontiers in Bioscience, 2009
View PDFchevron_right
ErbB2 Immune Response in Breast Cancer Patients with Soluble Receptor Ectodomain
Vincenzo Visco
The American Journal of Pathology, 2000
View PDFchevron_right
Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study
Juan Carlos Mellidez
Pulmonology, 2021
View PDFchevron_right
Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study
Andrea Michelotti
Journal of Cancer, 2014
View PDFchevron_right
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
Michele Tursi
Journal of Cancer Research and Clinical Oncology, 2013
View PDFchevron_right
ErbB-2 receptor cooperates with E6/E7 oncoproteins of HPV type 16 in breast tumorigenesis.
Ala-Eddin Al Moustafa
Cell cycle ( …, 2007
View PDFchevron_right
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes
S.B love
British Journal of Cancer, 1991
View PDFchevron_right